Bli medlem
Bli medlem

Du är här

2016-12-20

Immunovia AB: Immunovia announces the start of PANFAM-1, the largest ever prospective multi-center clinical study for early detection of pancreatic cancer

Designed to validate IMMrayTM PanCan-d, the first blood-based test for
early detection of pancreatic cancer.

LUND, Sweden, and MADRID, Spain - Immunovia AB today announced the
start of PANFAM-1, a multicenter prospective validation study for the
early diagnosis in familiar pancreatic cancer (FPC) high risk
individuals. The first site now collecting blood samples is the
Spanish research center Ramon y Cajal Institute for Health Research
(IRYCIS) in Madrid. Designed to validate Immunovia ?s blood test,
IMMrayTM PanCan-d, the study will run for three years across sites in
both the US and Europe offering FPC screening programs.

Pancreatic cancer continues to have one of the poorest survival rates
of any major cancer type. It is widely acknowledged, that the key to
improving prognosis and possible successful surgical intervention
lies in early detection. Following years of research, Immunovia has
developed the first blood based biomarker test to be validated in FPC
high risk individuals undergoing annual screening for early
pancreatic cancer detection.

"Since 2015, we have been conducting a surveillance program for
familiar pancreatic cancer high risk individuals in our center," says
Professor Carrato, Director of the Medical Oncology Department and
Scientific Director at IRYCIS. "The experience gained has taught us
that early detection can lead to successful surgical intervention and
to better patient management. For this reason, an accurate reliable
blood based test is needed. We are delighted to begin the prospective
validation of IMMrayTM PanCan-d as part of our surveillance program
of familiar pancreatic cancer high risk individuals and we are
looking forward to the results."

"For Immunovia, the start of the prospective validation of IMMray TM
PanCan-d is a critical milestone which will provide us with the
clinical evidence for the test. This longitudinal clinical study,
which will analyse one thousand familiar pancreatic cancer high risk
individuals over a three year period, will play a major role in the
regulatory and reimbursement applications of our test," commented
Mats Grahn, CEO, Immunovia.

Other confirmed PANFAM-1 partners, also shortly due to commence sample
collection, are Mount Sinai in New York and Knight Cancer Institute
at Oregon Health and Sciences University, Portland, USA and the
University of Liverpool, UK. Immunovia is also in discussions with
several other high risk surveillance programs from Europe and USA
about their participation.

For more information, please contact:

Mats Grahn

Chief Executive Officer, CEO, Immunovia

Tel.: +46-70-5320230

Email: mats.grahn@immunovia.com

Soraya Pérez

Communication, Hospital Ramón y Cajal (HRC)

Tel.: +34 91 336 89 32 / +34 91 336 90 67

Email: soraya.perez@salud.madrid.org /
comunicacion.hrc@salud.madrid.org

About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department
of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's
strategy is to decipher the wealth of information in blood and
translate it into clinically useful tools to diagnose complex
diseases such as cancer, earlier and more accurately than previously
possible. Immunovia's core technology platform, IMMray™, is based on
antibody biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early diagnosis
of pancreatic cancer. In the beginning of 2016, the company started a
program focused on autoimmune diseases diagnosis, prognosis and
therapy monitoring. The first test from this program, IMMray™ SLE-d,
is a biomarker signature derived for differential diagnosis of lupus,
now undergoing evaluation and validation. (Source: www.immunovia.com)

This information is information that Immunovia AB is obliged to make
public pursuant to the EU Market Abuse Regulation. The information
was submitted for publication, through the agency of the contact
person set out above.

Immunovia's shares (IMMNOV) are listed on Nasdaq First North in
Stockholm and Wildeco is the company's Certified Adviser. For more
information, please visit www.immunovia.com.

###

-----------------------------------------------------------
http://news.cision.com/immunovia-ab/r/immunovia-announces-the-start-of-p...
http://mb.cision.com/Main/13121/2153456/606045.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.